PLAU and neoplasm: Diphtheria toxin produced by Corynebacterium diphtheria is not efficient in cancer therapeutics, but it’s modified form DT modified with the amino terminal (AT) fragment of urokinase- type plasminogen activator (DTAT) has been tested on cell lines and murine model and reported to target vascular endothelial of the tumor, reduced tumor size (73) and resulted in significant regression of human U118MG tumor induced in nude mice (74, 75).